Our results show that miR-122 regulates cell proliferation through the PI3K/Akt/mTOR/p70S6K signaling pathway and exogenous overexpression of miR-122 may represent a promising approach for targeted BC therapies. This evidence concerns the gene RPS6KB1 and breast cancer.